Gland Pharma Limited has informed the Exchange about Options to purchase securities
GLAND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Gland Pharma's ESOP Compensation Committee approved the grant of 1,626 Employee Stock Options to 1 employee under the ESOP 2025 scheme on March 03, 2026. Of these, 1,073 options are priced at ₹897.40 per share (50% of the NSE closing price on March 02, 2026, since March 03 was a trading holiday), and 553 options are priced at ₹1 (face value). The options will vest in three tranches: 34% on March 03, 2027, 33% on March 03, 2028, and 33% on March 03, 2029, with a maximum exercise window of two years from each vesting date. The grant complies with SEBI's Share Based Employee Benefits and Sweat Equity Regulations, 2021.
This is a small, routine ESOP grant with minimal dilution (1,626 shares). It is unlikely to have any material impact on the stock price or existing shareholders, though it signals continued use of stock-based compensation to retain talent.